Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE, RP1 Clinical Trial Not Allowed)
🏛 National Institutes of Health (HHS-NIH11)
✓ Free, no account · Source: Grants.gov · Last verified Jul 15, 2026
Can you apply?
This grant is for research institutions and cancer biology investigators studying radiopharmaceutical therapy (RPT) using preclinical models. Eligible applicants typically include academic medical centers, research institutes, and nonprofit organizations with appropriate research infrastructure. The program supports exploratory/developmental projects (up to 2 years) or research projects (4-5 years). Clinical trials and RP1 clinical studies are explicitly not eligible.
Not the right fit? Find grants for your organization in 5 questions →
Key dates
- Mar 11, 2026 Applications open
- Oct 5, 2026 Application deadline in 81 days
- Jul 1, 2027 Award announced
- Jul 1, 2027 Project start
Program description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) intends to support research projects that employ state-of-the-art cancer biology approaches and preclinical model systems to investigate the biological effects of radiation emitted by radionuclides used in radiopharmaceutical therapy (RPT). The focus of this initiative is to advance mechanistic understanding of how different forms of radionuclide-emitted radiation affect normal tissues, tumor cells, and the tumor microenvironment, and how these effects can be leveraged to improve therapeutic outcomes. This NOFO will support the Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) program. The overarching goal of STRIPE is to stimulate multidisciplinary research that integrates cancer biology, radiation biology, radiochemistry, imaging, dosimetry, and preclinical modeling. Funded projects are expected to generate fundamental biological insights that can serve as the foundation for the development of new targeting strategies, optimized treatment regimens, and innovative combination approaches for RPT, ultimately leading to more effective and precise anticancer therapies.
This NOFO consolidates prior exploratory/developmental and research project funding mechanisms to streamline the application process and sustain momentum in this critical research area. The applicants have the option of submitting either for exploratory/developmental research projects with a project period of up to 2 years or for research projects with a project period of 4 to 5 years. Collectively, the STRIPE program is intended to broaden the scientific base of RPT research, lower barriers to entry for cancer biology investigators, and accelerate the generation of reproducible, mechanistically informed data that will enable more effective and personalized use of radiopharmaceutical therapies in cancer care.
Who can apply
Eligible applicants
How to apply
Application links
Key dates & requirements
Required documents
- NIH R&D Form 424 (SF-424)
- Project Narrative/Research Strategy
- Budget and Budget Justification
- Biographical Sketch (NIH Form 5)
- Institutional Support Letter
- Letters of Collaboration (if applicable)
Program contact
- 👤 STRIPE-Program NCI
- 📧 STRIPE-ProgramContact@mail.nih.gov
- 📞 Phone: 240-276-5690
Funding track record
Recent awards under CFDA 93.395 from the last 3 years — real organizations that won funding through this same program.
Top 10 Largest Recent Awards
-
$353,109,533
-
$226,323,195
-
$180,463,644
-
$148,820,579
-
$143,093,026
-
$125,672,442
-
$124,513,663
-
$112,462,142
-
$109,067,856
-
$104,790,648
Top States by Funding
- CA 10 awards $871.7M
- PA 5 awards $513.3M
- NY 7 awards $462.6M
- MA 7 awards $282.7M
- IL 3 awards $274.4M
Source: USAspending.gov — federal spending transparency. Data covers last 3 years.
Funding history
Annual funding for this program — Federal obligations (CFDA 93.395). How funding has trended year over year.
| 2024 | $1,298,551,504 | |
| 2025 | $1,414,965,434 | |
| 2026 est. | $926,626,977 |
FAQ
Who can apply for STRIPE funding?
Research institutions, universities, and nonprofit research organizations with cancer biology or radiation biology expertise can apply. Individual investigators must be at eligible institutions.
What types of projects are supported?
Exploratory/developmental projects (up to 2 years) and research projects (4-5 years). Clinical trials and RP1 clinical studies are not allowed.
What is the deadline?
October 5, 2026 is the fixed deadline for this funding opportunity.
What research areas does STRIPE focus on?
Projects must investigate biological effects of radionuclide radiation in preclinical models, cancer biology, radiation biology, and radiochemistry relevant to radiopharmaceutical therapy.
Do I need to provide cost-sharing?
No cost-sharing is required for this grant.
💡 Tips for applicants
- Focus on mechanistic understanding of how radionuclides affect tumor cells and normal tissues in preclinical models. Avoid clinical trial designs.
- Demonstrate integration of multiple disciplines: cancer biology, radiation biology, radiochemistry, and dosimetry.
- Use state-of-the-art preclinical model systems and explain why your models are appropriate for investigating radiation effects.
- Clearly articulate how your findings could advance radiopharmaceutical therapy development and personalized cancer treatment.
- Include preliminary data showing feasibility of your proposed preclinical experiments.
⚠️ Common mistakes
Proposing clinical trials or RP1 human studies (not eligible). Submitting projects without clear mechanistic focus on radiation biology effects. Failing to demonstrate multidisciplinary integration across required research areas.
Similar grants
- OPEN Early-Stage Innovative Technology Development for Basic and Clinical Cancer Research (R61 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional) — National Institutes of Health
- OPEN Advanced Development and Validation of Emerging Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01 Clinical Trial Not Allowed) — National Institutes of Health
- OPEN Ancillary Studies to Ongoing Clinical Projects (RP1 Clinical Trial Not Allowed) — National Institutes of Health